Receive our newsletter – data, insights and analysis delivered to you
  1. Comment
December 11, 2019updated 13 Dec 2019 11:52am

Blockbuster-to-be for depression flunks pivotal Phase III

Sage Therapeutics was aiming to enter a bigger market, through the potential launch of SAGE-217.

By GlobalData Healthcare

Sage Therapeutics’ SAGE-217 missed its primary endpoint in a key Phase III trial for major depressive disorder (MDD), resulting in a major blow for the neurology-specialist company.

Although this does not scrap the pipeline asset from clinical trials, investors rapidly responded to this R&D setback by wiping out almost 60% off its share price.

In March 2019, Sage Therapeutics’ Zulresso (brexanolone) gained FDA approval for postpartum depression, securing first-to-market position, but also the company’s first drug to reach the market. Subsequently, Sage Therapeutics was aiming to enter a bigger market, MDD, through the potential launch of SAGE-217.

Earlier this year, SAGE-217 met its primary and secondary endpoints in the Phase III ROBIN study in postpartum depression. It also demonstrated positive results from an earlier Phase II trial in severe MDD. SAGE-217 was viewed as being commercially attractive for the company, given that this drug is oral and would capture a much larger patient pool, while Zulresso’s high price point and a 60-hour infusion could hinder its uptake. Ultimately, SAGE-217 could have been a blockbuster, and its novel mechanism of action would have been well received in the crowded MDD market. As such, the company had high hopes, but trials for mood disorders are notoriously challenging.

The recent news demonstrated that SAGE-217 barely outperformed placebo in the pivotal Phase III MOUNTAIN trial for MDD. The company has noted that patient non-compliance could be to blame for these disappointing results. Additionally, selection factors could have influenced results, as the trial included a higher proportion of patients with less severe symptoms. Fortunately, SAGE-217’s safety profile was positive and the company is now waiting for data from the other studies the product is currently undergoing.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU